Abstract:Backeround and aims: Bone morphogenetic proteins (BMPs) play important roles in the development and progression of breast cancer via the regulation of cellular proliferation, differentiation, apoptosis, motility of tumor cells and angiogenesis. BMP-12 is a new member of the BMP family and has been implicated in the development of certain tissues. However, its role in breast cancer is largely unknown. The current study investigated the expression pattern of BMP-12 in a breast cancer cohort and evaluated the possible correlation between BMP-12 and clinical and pathological features. Method: BMP-12 transcripts were examined in a variety of breast cancer cell lines using RT-PCR. The expression of BMP-12 transcripts in primary breast cancer tissues (n=112) and normal mammary tissues (n=31) was determined using quantitative real time PCR. The expression and cellular distribution of BMP-12 was further examined using immunohistochemical staining. The transcript level of BMP-12 was analysed against the clinical, pathological and follow-up (10 years) data. Results: BMP-12 transcript was detected at a lower level in breast cancer cell lines and breast tumour tissues. Immunohistochemical staining revealed significantly lower levels of BMP-12 staining in breast tumors than in normal tissues. It showed a trend that BMP-12 transcript levels were higher in tumors from patients with a good prognosis compared with those with a poor prognosis. Tumors from patients with longer overall survival also had a higher level of the transcript than those from patients with a shorter survival. Conclusion: BMP-12 expression is decreased in breast tumors, and is correlated with poor prognosis. It suggests that BMP-12 may be an inhibitory factor during the disease progression and may have potential prognostic implications in breast cancer.

The aberrant expression of bone morphogenetic protein 12 (BMP-12) in human breast cancer and its potential prognostic value